Tackling Allogeneic Immunotherapy's Scale-up Bottleneck with the PBS Biotech Vertical-Wheel® Bioreactor
Introduction
Researchers have tapped into the potential of other immune cells for immunotherapy, including natural killer (NK) cells, which help the immune system monitor cancerous threats and can directly kill tumor cells. NK cells are much less likely to cause cytokine release syndrome, making them particularly promising as an allogeneic immunotherapy Nevertheless, their widespread development is hindered by production scale-up challenges. Traditional expansion platforms typically used for autologous therapies cannot meet the scale required for commercial allogeneic therapies.
